Patents Assigned to KITOV PHARMACEUTICAL LTD.
  • Patent number: 9662315
    Abstract: Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: May 30, 2017
    Assignee: Kitov Pharmaceuticals Ltd.
    Inventors: Peter C. Hoyle, Paul Waymack
  • Publication number: 20160243134
    Abstract: An oral dosage form of a non-steroidal anti-inflammatory drug (NSAID) is rendered safer for extended or chronic use for anti-inflammatory, analgesic or antipyretic therapy by combining it with an antihypertensive drug. The antihypertensive drug acts prophylactically to inhibit or reduce NSAID-induced hypertension and by so doing the adverse cardiovascular side effects of NSAIDs, such as high blood pressure, heart attack, stroke, opththamologic complications, and death, when NSAIDs are used repetitively over an extended period of time for reducing inflammation or in pain management.
    Type: Application
    Filed: May 2, 2016
    Publication date: August 25, 2016
    Applicant: Kitov Pharmaceuticals Ltd.
    Inventors: Peter C. Hoyle, Paul Waymack
  • Patent number: 9408837
    Abstract: Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are atrisk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.
    Type: Grant
    Filed: February 14, 2011
    Date of Patent: August 9, 2016
    Assignee: Kitov Pharmaceutical Ltd.
    Inventors: Peter C. Hoyle, Paul Waymack
  • Publication number: 20160058744
    Abstract: Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 3, 2016
    Applicants: JPW PCH, INC., KITOV PHARMACEUTICAL LTD.
    Inventors: Peter C. Hoyle, Paul Waymack